Navigation Links
Adding a genetic supertool

To identify the hemophilia mutation that affected Queen Victoria and her European relatives, scientific detectives used a cutting-edge "deep sequencing tool." Able to trace rare genetic disease mutations, the tool can turn a single laboratory into a fertile genetic research center.

Now, Tel Aviv University has its own deep sequencer one of the first in Israel a Genome Analyzer housed in a new Genome Facility.

The tool will add an important new capability to Tel Aviv University research, including identifying DNA's micro-managers, small micro-RNA that regulate how our genes work. In the world of medicine, it has already uncovered virtually undetectable traces of cancer, and in ecological research, it has been able to sequence the genes of insects to understand how they adapt to different diets in a changing world.

A cure for deafness within earshot

At Tel Aviv University, scientists have ambitious plans for their Genome Analyzer. Prof. Karen Avraham, of the Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine at Tel Aviv University, is already using it to try to discover the root cause of genetic deafness and make a cure for deafness reachable in the next decade.

"Tel Aviv University will use the Genome Analyzer to rapidly advance genomic research," says Prof. Avraham. "Our focus is on newly identified gene regulators we call microRNAs the super-stars of gene research in this decade that act as controllers of gene expression in health and disease. MicroRNAs are believed to control as much as 50 percent of our genes and to regulate many cellular pathways," she says.

"In the work at Tel Aviv University, the deep sequencer provides us with the ability to identify more critical microRNAs for example, in stem cells, in the inner ear system, and in the RNA that cause susceptibility to viral infection," says Prof. Avraham.

Purchased with a grant to the Tel Aviv University MicroRNA Consortium from the UK-based Wolfson Foundation Charitable Trust, the Sackler School of Medicine and the George S. Wise Faculty of Life Sciences new Genome Analyzer sequencing system and another at the TAU-affiliated Sheba Medical Center hospital give Tel Aviv University the processing power of hundreds of previous version sequencing machines in order to compete with researchers anywhere in the world.

A crystal ball for a cancer cure

This new equipment will affect TAU's work in Life Sciences across the board. "This is a new frontier in science, and it will impact all areas of research that we do targeting treatments for cancer and rare and common genetic diseases," says Prof. Avraham, who coordinated obtaining the consortium's efforts.

Prof. Gil Ast of the Department of Human Genetics, Sackler School of Medicine, is another of the pioneering researchers at Tel Aviv University who are using the deep sequencing tool. Among his projects is the exploration of curative possibilities for rare genetic diseases, and unlocking the biology of DNA assembly.

It will be also used by young researchers such as Dr. Noam Shomron, who will also run the facility. Using a deep sequencer tool, Dr. Shomron is working in the rapidly developing area of "personalized medicine", investigating why some patients respond well to chemotherapy while others do not. He is building detailed genetic profiles with the potential to shape specialized treatments for patients and exploring the use of microRNA for "smart drugs" that can target individual and damaged cells.


Contact: George Hunka
American Friends of Tel Aviv University

Related medicine news :

1. Adding Chemo to Tamoxifen Helps Some Breast Cancer Patients
2. Adding Proton Therapy Boost to X-Ray Radiation Therapy Reduces Prostate Cancer Recurrences
3. Adding Chemo Helps Head, Neck Cancer Patients
4. Adding tools against breast tumors
5. Adding Drug Doesnt Help Control Blood Pressure
6. CutisPharma Launches New Prescription Mouthwash Kit Adding to Product Line
7. Adding a Stent May Help Resolve Brain Aneurysm
8. Dakim BrainFitness Now Used in 286 Senior Living Communities, Adding 136 Sites in 12 Months for Dementia-Fighting System
9. Hospital Improves Patient Experience by Adding Email and Web Access in Patient Rooms With Virtual Linux Desktops
10. Contracts adding legal twist to family health care
11. Takeda to Acquire IDM Pharma, Adding MEPACT(R) (Mifamurtide), the First Treatment Approved for Osteosarcoma in More Than 20 Years, to Its Oncology Franchise
Post Your Comments:
Related Image:
Adding a genetic supertool
(Date:11/25/2015)... , ... November 25, 2015 , ... ... has been recognized once again for its stellar workplace culture with the company’s ... , Medical Solutions’ Cincinnati office was named a finalist in Cincinnati ...
(Date:11/25/2015)... ... November 26, 2015 , ... ... European Union (EU), ANDI Pan African Centres of Excellence, and public R&D institutions, ... (UNON) for the opening of the 5th African Network for Drugs and Diagnostics ...
(Date:11/25/2015)... Angeles, CA (PRWEB) , ... November 25, 2015 , ... ... da Vinci surgical robot is being more and more widely heralded as a breakthrough ... assisted da Vinci method has over traditional laparoscopic surgery is that it can greatly ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug ... a new cutting edge recovery program that has been 50 years in the making. ... individuals with the purpose to free addicts from the symptoms and negative behaviors of ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 23rd 2015 Cozy ... personal heating products business. Cozy Products explains what this means for business moving ... well with the Cozy Products business model: to sell personal heaters that reduce energy ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... Nov. 25, 2015 AAIPharma Services Corp./Cambridge ... of at least $15.8  Million to expand its ... NC . The expansion will provide additional ... the growing demands of the pharmaceutical and biotechnology ... expansion will provide up to 40,000 square feet ...
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ), a ... start-up  biotechnology company focused on the development of ... by the F-Prime Biomedical Research Initiative (FBRI), today ... collaboration to support the discovery and development of ... Obsessive Compulsive disorders (OCD). ...
Breaking Medicine Technology: